文献速递精神分裂症与精神病性障碍会诊联络精神医学

英国严重精神疾病患者启动抗精神病药后HbA1c与体重变化:个体水平间断时间序列分析

Change in HbA1c and weight after initiation of antipsychotic treatment in people with severe mental illness in England: an individual-level interrupted time-series analysis.
PubMed 文献 · Lancet Psychiatry · 2026-01-01

该研究基于英国临床实践研究数据链Aurum数据库2000至2023年电子健康记录,纳入96 849例18-59岁严重精神疾病患者,采用个体水平间断时间序列混合模型分析启动口服二代抗精神病药前后HbA1c与体重变化轨迹。结果显示启动后0-90天HbA1c与体重快速上升,91天至2年HbA1c增速回落至治疗前水平而体重仍缓慢增加;奥氮平增幅最大,女性增幅普遍更高。

要点

  • 启动二代抗精神病药后0-90天HbA1c与体重快速增加,91天至2年HbA1c增速回落而体重仍缓慢增加。
  • 奥氮平相关HbA1c与体重增幅最大,喹硫平体重增加明显但HbA1c变化很小。

核心结论

  • 启动抗精神病药治疗后前90天HbA1c与体重快速增加,随后至2年增速放缓但体重仍持续上升。
  • HbA1c与体重变化不完全一致,支持基线与12周同时监测两项指标,并进行风险分层监测与干预。

研究设计与样本

  • 研究为英国个体水平间断时间序列分析,使用临床实践研究数据链Aurum数据库2000年1月1日至2023年6月7日电子健康记录。
  • 纳入18-59岁严重精神疾病患者,要求首次抗精神病药处方后90天内至少开具第二种口服二代抗精神病药处方。
  • 采用个体水平间断时间序列混合模型与线性样条,估计治疗前、启动后0-90天及91天至2年的HbA1c与体重变化速率。

临床怎么用

  • 对启动二代抗精神病药治疗的严重精神疾病患者,应在基线及12周监测HbA1c与体重。
  • 根据基线血糖状态与所用药物进行风险分层监测与干预,尤其关注奥氮平使用者和女性患者。

局限性

  • 研究为观察性电子健康记录分析,不能确立因果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Second-generation antipsychotics contribute to excess cardiometabolic morbidity in people with severe mental illness, but the timing of early glycaemic change and whether it parallels weight gain remain unclear. We aimed to evaluate glycated haemoglobin A1c (HbA1c) and weight trajectories before and after initiation of antipsychotic treatment. METHODS: We conducted an individual-level interrupted time-series analysis in England using electronic health records (EHR) from the Clinical Practice Research Datalink Aurum database between Jan 1, 2000, and June 7, 2023. Included participants were aged 18-59 years with severe mental illness (SMI) who had at least a second oral second-generation antipsychotic prescription issued within 90 days from their first antipsychotic prescription. Individuals were excluded if they had dementia, type 2 diabetes, or antipsychotic prescriptions before age 18 years. The exposure was the first recorded oral initiation of antipsychotic treatment. We used individual-level, interrupted time-series mixed models with linear splines to estimate rates of change in HbA1c and weight in people with SMI before treatment initiation, 0-90 days after initiation, and from 91 days to 2 years after initiation. An additional outcome was time to type 2 diabetes diagnosis or antidiabetic medication prescription. Analyses were stratified by sex, antipsychotic drug, and baseline glycaemic status. People with lived experience contributed to the research question, study approach, interpretation, and dissemination. FINDINGS: Of the 96 849 eligible individuals, 53 558 (55·3%) were male and 43 291 (44·7%) were female. The mean age of participants was 37·2 years (SD 11·1; range 18-59); 62 683 (64·7%) reported their ethnicity as White, 5952 (6·1%) as south Asian, 6736 (7·0%) as Black, 3793 (3·9%) as other or mixed ethnicity, and 17 693 (18·3%) had missing ethnicity. 74 233 (76·6%) individuals had at least one recorded weight measurement and 24 084 (24·9%) had at least one HbA1c measurement. In the pre-treatment period, HbA1c increased at a rate of 0·01 mmol/mol per week (95% CI 0·00-0·01) and weight at a rate of 0·02 kg (0·02-0·02) per week. In the 0-90 days following antipsychotic treatment initiation, HbA1c increased at a rate of 0·12 mmol/mol per week (0·09-0·15) and weight at 0·21 kg (0·20-0·22) per week. From day 91 to 2 years, the rate of increase of HbA1c returned to pre-treatment levels (0·01 mmol/mol per week [0·00-0·01]) and weight increased at 0·03 kg (0·02-0·03) per week. Increases were largest for olanzapine (HbA1c 0·18 mmol/mol per week [95% CI 0·12-0·25]; weight 0·28 kg [0·27-0·30]) and generally higher among women (HbA1c 0·14 mmol/mol [0·09-0·18]; weight 0·22 kg [0·21-0·23]). Quetiapine was associated with weight gain (0·19 kg per week [95% CI 0·18 to 0·21]), but minimal HbA1c change (0·02 mmol/mol [-0·03 to 0·08]). Among 918 individuals with baseline prediabetes, 126 (13·7%)developed type 2 diabetes, corresponding to an estimated 2-year cumulative incidence of 19·0%, compared with 152 (1·7%) of 9171 individuals with normal baseline HbA1c, corresponding to an estimated 2-year cumulative incidence of 3·0%. INTERPRETATION: Antipsychotic treatment initiation was followed by rapid HbA1c and weight increases in the first 90 days followed by slower increases up to 2 years. Imperfect concordance between HbA1c and weight supports baseline and 12-week monitoring of both outcomes, followed by risk-stratified monitoring and intervention. FUNDING: National Institute for Health and Care Research (NIHR) Three Research Schools Mental Health Programme, NIHR School for Primary Care Research, NIHR Applied Research Collaboration West Midlands, NIHR Dementia and Neurodegeneration Policy Research Unit, UK Research and Innovation, University College London Hospitals NIHR Biomedical Research Centre, and NIHR North Thames Applied Research Collaboration.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Bazo-Alvarez JC, Stone PW, Avgerinou C, et al. Change in HbA1c and weight after initiation of antipsychotic treatment in people with severe mental illness in England: an individual-level interrupted time-series analysis. Lancet Psychiatry. 2026. PMID: 42874604. doi:10.1016/S2215-0366(26)00274-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。